Direct Investments

Lifesciences portfolio company receives £2.4million investment

Medherant patch

Mercia has today announced an additional £2.0million direct investment as part of a circa
£2.4million syndicated investment round into Medherant the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®.

Mark Payton, Chief Executive Officer at Mercia Technologies PLC, said: “Medherant represents Mercia’s second largest investment within our direct investment portfolio of Life Science & Biosciences companies, which combined account for circa 25% of our direct investment portfolio by value. We are encouraged by the progress the team is making and this latest round of syndicated investment will support the continued development of Medherant’s suite of unique transdermal patches, targeted at attractive high-growth markets with significant unmet medical needs.”

You can read the full RNS here.